While the mechanism of activation of CDC42/RAC1 by RHOG, the MAPK by RAC1, as well as the intersection with the RHOA/ROCK1/2 pathways remain topics for future work, we believe this study sheds the light on RHOG as a potentially promising target for anti-angiogenesis in cancer therapeutics. Here, RHOG is linked to cancer.